Lambert-Eaton myasthenic syndrome (LEMS) in a patient with lung cancer under treatment with pembrolizumab: a case study.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2022.2073162
Abstract: Pembrolizumab is an immune checkpoint inhibitor (ICI) against the programmed death-1 receptor. Herein, we introduce a rare adverse effect during using pembrolizumab. We present the case of an 80-year-old man with biopsy-proven unresectable double primary… read more here.
Keywords: syndrome lems; myasthenic syndrome; eaton myasthenic; lambert eaton ... See more keywords